Bristol Myers’ BMS-986278 yields promising results in slowing pulmonary fibrosis progression in Phase 2 trial
Bristol Myers Squibb (NYSE: BMY) disclosed a pivotal Phase 2 study highlighting that BMS-986278, an investigational oral LPA1 antagonist, reduces the rate of lung function decline in patients with Progressive Pulmonary Fibrosis (PPF) by 69% compared to a placebo. The study, conducted over 26 weeks, involved twice-daily administration of 60 mg of BMS-986278 and will […]
